Combination chemotherapy and rituximab

Anti-Cancer Drugs

Volumn 12, Issue SUPPL. 2, 2001, Pages

  Czuczman, M S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Chemoimmunotherapy; CHOP chemotherapy; Fludarabine; Low grade lymphoma; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TUMOR MARKER; VINCRISTINE;

CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; GENE TRANSLOCATION; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; PREDNISOLONE; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; VIDARABINE; VINCRISTINE;

EID: 0034959580     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Cancer Statistics, 2000
2. The rise in incidence of lymphomas in Europe 1985-1992
3. Coherent view of non-Hodgkin's lymphoma
4. Monoclonal antiidiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells
5. Monoclonal anti-idiotype therapy of B-cell lymphoma
6. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
7. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
8. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
9. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
10. CHOP versus MACOP-B in aggressive lymphoma - A Nordic Lymphoma Group randomised trial
11. Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: A pilot study
12. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy
13. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomised trial from the Lymphoma Group of Central Sweden
14. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
15. Lymphocytic lymphomas
16. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
17. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
18. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia
19. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia
20. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group
21. Fludarabine: A phase II trial in patients with previously treated low-grade lymphoma
22. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte